Hyloris Pharmaceuticals SA HYL

EURONEXT · Belgium · Health Technology

€4.25-0.06 (-1.39%)

Market closed· Oct 1, 2026, 3:35 PM UTC· EUR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Hyloris Pharmaceuticals SA HYL

EURONEXT · Belgium · Health Technology

€4.25-0.06 (-1.39%)

Market closed· Oct 1, 2026, 3:35 PM UTC· EUR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-16.67% · 6MFull-screen chart

Open €4.21High €4.24Low €4.11Close €4.25Volume 6.45K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: €4.31
Day range: €4.11 – €4.24
52-week range: €4.05 – €8.40
Volume: 6.45K
Market cap: €120.68M
Next earnings date: 2027-03-17
Avg. volume (1Y): 5.99K

Performance

1 week

-7.41%

1 month

-5.35%

3 months

-5.97%

6 months

-9.57%

Year to date

-40.81%

1 year

-28.69%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Belgium
Exchange: EURONEXT
Shares outstanding: 28.00M
Employees: 55
ISIN: BE0974363955
Beta: 1.01

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMay 20, 2026

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum Mont-Saint-Guibert, Belgium – May 20, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today participated in an exclusive afternoon organized at LégiaPark, the life sciences innovati

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.